SEARCH

SEARCH BY CITATION

References

  • AJUEBOR, M.N., SINGH, A. & WALLACE, J.L. (2000). Cyclooxygenase-2-derived prostaglandin D2 is an early anti-inflammatory signal in experimental colitis. Am. J. Physiol., 279, G238G244.
  • APPLEBY, S.B., RISTIMAKI, A., NEILSON, K., NARKO, K. & HLA, T. (1994). Structure of the human cyclo-oxygenase-2 gene. Biochem. J., 302, 723727.
  • BOMBARDIER, C., LAINE, L., REICIN, A., SHAPIRO, D., BURGOS-VARGAS, R., DAVIS, B., DAY, R., FERRAZ, M.B., HAWKEY, C.J., HOCHBERG, M.C., KVIEN, T.K. & SCHNITZER, T.J. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med., 343, 15201528.
  • BONNER, G.F. (2001). Exacerbation of inflammatory bowel disease associated with use of celecoxib. Am. J. Gastroenterol., 96, 13061308.
    Direct Link:
  • CHENG, H.F. & HARRIS, R.C. (2004). Cyclooxygenases, the kidney, and hypertension. Hypertension, 43, 525530.
  • CLARIA, J., LEE, M.H. & SERHAN, C.N. (1996). Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)–neutrophil interactions and are potent inhibitors of cell proliferation. Mol. Med., 2, 583596.
  • CROFFORD, L.J., OATES, J.C., MCCUNE, W.J., GUPTA, S., KAPLAN, M.J., CATELLA-LAWSON, F., MORROW, J.D., MCDONAGH, K.T. & SCHMAIER, A.H. (2000). Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Arthritis Rheum., 43, 18911896.
  • DAVIES, N.M., SHARKEY, K.A., ASFAHA, S., MACNAUGHTON, W.K. & WALLACE, J.L. (1997). Aspirin causes rapid up-regulation of cyclo-oxygenase-2 expression in the stomach of rats. Aliment. Pharmacol. Ther., 11, 11011108.
  • DEVCHAND, P.R., ARITA, M., HONG, S., BANNENBERG, G., MOUSSIGNAC, R.L., GRONERT, K. & SERHAN, C. (2003). Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J., 17, 652659.
  • DEWITT, D.L., EL-HARITH, E.A., KRAEMER, S.A., ANDREWS, M.J., YAO, E.F., ARMSTRONG, R.L. & SMITH, W.L. (1990). The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J. Biol. Chem., 265, 51925198.
  • EHRLICH, K., SICKING, C., RESPONDEK, M. & PESKAR, B.M. (2004). Interaction of cyclooxygenase isoenzymes, nitric oxide, and afferent neurons in gastric mucosal defence in rats. J. Pharmacol. Exp. Ther., 308, 277283.
  • ERICKSON, B.A., LONGO, W.E., PANESAR, N., MAZUSKI, J.E. & KAMINSKI, D.L. (1999). The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J. Surg. Res., 81, 101107.
  • FIORUCCI, S., DE LIMA Jr, O.M., MENCARELLI, A., PALAZZETTI, B., DISTRUTTI, E., MCKNIGHT, W., DICAY, M., MA, L., ROMANO, M., MORELLI, A. & WALLACE, J.L. (2002). Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology, 123, 15981606.
  • FIORUCCI, S., DISTRUTTI, E., DE LIMA, O.M., ROMANO, M., MENCARELLI, A., BARBANTI, M., PALAZZINI, E., MORELLI, A. & WALLACE, J.L. (2003a). Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J., 17, 11711173.
  • FIORUCCI, S., SANTUCCI, L., WALLACE, J.L., SARDINA, M., ROMANO, M., DEL SOLDATO, P. & MORELLI, A. (2003b). Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc. Natl. Acad. Sci. U.S.A., 100, 1093710941.
  • GILROY, D.W., COLVILLE-NASH, P.R., MCMASTER, S., SAWATZKY, D.A., WILLOUGHBY, D.A. & LAWRENCE, T. (2003). Inducible cyclooxygenase-derived 15-deoxy-Δ12−14PGJ2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis. FASEB J., 17, 22692271.
  • GILROY, D.W., COLVILLE-NASH, P.R., WILLIS, D., CHIVERS, J., PAUL-CLARK, M.J. & WILLOUGHBY, D.A. (1999). Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med., 5, 698701.
  • GRETZER, B., MARICIC, N., RESPONDEK, M., SCHULIGOI, R. & PESKAR, B.M. (2001). Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br. J. Pharmacol., 132, 15651573.
  • GROSSER, T., YUSUFF, S., CHESKIS, E., PACK, M.A. & FITZGERALD, G.A. (2002). Developmental expression of functional cyclooxygenases in zebrafish. Proc. Natl. Acad. Sci. U.S.A., 99, 84188423.
  • HALTER, F., TARNAWSKI, A.S., SCHMASSMANN, A. & PESKAR, B.M. (2001). Cyclooxygenase 2 – implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut, 49, 443453.
  • HERNANDEZ, L.A., GRISHAM, M.B., TWOHIG, B., ARFORS, K.E., HARLAN, J.M. & GRANGER, D.N. (1987). Role of neutrophils in ischemia–reperfusion-induced microvascular injury. Am. J. Physiol., 253, H699H703.
  • HLA, T. & NEILSON, K. (1992). Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. U.S.A., 89, 73847388.
  • ITZKOWITZ, S.H. & YIO, X. (2004). Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol., 287, G7G17.
  • JONES, M.K., WANG, H., PESKAR, B.M., LEVIN, E., ITANI, R.M., SARFEH, I.J. & TARNAWSKI, A.S. (1999). Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med., 5, 14181423.
  • KARGMAN, S., CHARLESON, S., CARTWRIGHT, M., FRANK, J., RIENDEAU, D., MANCINI, J., EVANS, J. & O'NEILL, G. (1996). Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology, 111, 445454.
  • KENNEDY, B.P., CHAN, C.C., CULP, S.A. & CROMLISH, W.A. (1993). Cloning and expression of rat prostaglandin endoperoxide synthase (cyclooxygenase)-2 cDNA. Biochem. Biophys. Res. Commun., 197, 494500.
  • LAINE, L., MALLER, E.S., YU, C., QUAN, H. & SIMON, T. (2004). Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology, 127, 395402.
  • LANGENBACH, R., MORHAM, S.G., TIANO, H.F., LOFTIN, C.D., GHANAYEM, B.I., CHULADA, P.C., MAHLER, J.F., LEE, C.A., GOULDING, E.H. & KLUCKMAN, K.D. (1995). Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell, 83, 483492.
  • LECOMTE, M., LANEUVILLE, O., JI, C., DEWITT, D.L. & SMITH, W.L. (1994). Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J. Biol. Chem., 269, 1320713215.
  • MA, L., DEL SOLDATO, P. & WALLACE, J.L. (2002). Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance. Proc. Natl. Acad. Sci. U.S.A., 99, 1324313247.
  • MA, L., ELLIOTT, S.N., CIRINO, G., BURET, A., IGNARRO, L.J. & WALLACE, J.L. (2001). Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc. Natl. Acad. Sci. U.S.A., 98, 64706475.
  • MAMDANI, M., JUURLINK, D.N., LEE, D.S., ROCHON, P.A., KOPP, A., NAGLIE, G., AUSTIN, P.C., LAUPACIS, A. & STUKEL, T.A. (2004). Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet, 363, 17511756.
  • MANN, J.R. & DUBOIS, R.N. (2004). Cyclooxygenase-2 and gastrointestinal cancer. Cancer J., 10, 145152.
  • MARICIC, N., EHRLICH, K., GRETZER, B., SCHULIGOI, R., RESPONDEK, M. & PESKAR, B.M. (1999). Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia–reperfusion injury in the rat stomach. Br. J. Pharmacol., 128, 16591666.
  • MATUK, R., CRAWFORD, J., ABREU, M.T., TARGAN, S.R., VASILIAUSKAS, E.A. & PAPADAKIS, K.A. (2004). The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm. Bowel Dis., 10, 352356.
  • MITCHELL, J.A. & EVANS, T.W. (1998). Cyclooxygenase-2 as a therapeutic target. Inflamm. Res., 47 (Suppl 2), S88S92.
  • MIZUNO, H., SAKAMOTO, C., MATSUDA, K., WADA, K., UCHIDA, T., NOGUCHI, H., AKAMATSU, T. & KASUGA, M. (1997). Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology, 112, 387397.
  • MORHAM, S.G., LANGENBACH, R., LOFTIN, C.D., TIANO, H.F., VOULOUMANOS, N., JENNETTE, J.C., MAHLER, J.F., KLUCKMAN, K.D., LEDFORD, A. & LEE, C.A. (1995). Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell, 83, 473482.
  • MORTEAU, O., MORHAM, S.G., SELLON, R., DIELEMAN, L.A., LANGENBACH, R., SMITHIES, O. & SARTOR, R.B. (2000). Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J. Clin. Invest., 105, 469478.
  • MUKHERJEE, D., NISSEN, S.E. & TOPOL, E.J. (2001). Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 286, 954959.
  • MUKHOPADHYAY, D., HOUCHEN, C.W., KENNEDY, S., DIECKGRAEFE, B.K. & ANANT, S. (2003). Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a novel RNA binding protein, CUGBP2. Mol. Cell, 11, 113126.
  • MURMU, N., JUNG, J., MUKHOPADHYAY, D., HOUCHEN, C.W., RIEHL, T.E., STENSON, W.F., MORRISON, A.R., ARUMUGAM, T., DIECKGRAEFE, B.K. & ANANT, S. (2004). Dynamic antagonism between RNA-binding protein CUGBP2 and cyclooxygenase-2-mediated prostaglandin E2 in radiation damage. Proc. Natl. Acad. Sci. U.S.A., 101, 1387313878.
  • MUSCARÁ, M.N., VERGNOLLE, N., LOVREN, F., TRIGGLE, D.R., ELLIOTT, S.N., ASFAHA, S. & WALLACE, J.L. (2000). Selective cyclooxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br. J. Pharmacol., 129, 14231430.
  • NEWBERRY, R.D., MCDONOUGH, J.S., STENSON, W.F. & LORENZ, R.G. (2001). Spontaneous and continuous cyclooxygenase-2-dependent prostaglandin E2 production by stromal cells in the murine small intestine lamina propria: directing the tone of the intestinal immune response. J. Immunol., 166, 44654472.
  • NEWBERRY, R.D., STENSON, W.F. & LORENZ, R.G. (1999). Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nat. Med., 5, 900906.
  • O'BANION, M.K., WINN, V.D. & YOUNG, D.A. (1992). cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl. Acad. Sci. U.S.A., 89, 48884892.
  • OTT, E., NUSSMEIER, N.A., DUKE, P.C., FENECK, R.O., ALSTON, R.P., SNABES, M.C., HUBBARD, R.C., HSU, P.H., SAIDMAN, L.J. & MANGANO, D.T. (2003). Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg., 125, 14811492.
  • PERINI, R.F., MA, L. & WALLACE, J.L. (2003). Mucosal repair and COX-2 inhibition. Curr. Pharm. Res., 9, 22072211.
  • QIU, F.H., DEVCHAND, P.R., WADA, K. & SERHAN, C.N. (2001). Aspirin-triggered lipoxin A4 and lipoxin A4 up-regulate transcriptional corepressor NAB1 in human neutrophils. FASEB J., 15, 27362738.
  • REUTER, B.K., ASFAHA, S., BURET, A., SHARKEY, K.A. & WALLACE, J.L. (1996). Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J. Clin. Invest., 98, 20762085.
  • ROBERT, A., NEZAMIS, J.E., LANCASTER, C. & HANCHAR, A.J. (1979). Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology, 77, 433443.
  • ROWLEY, A.F. (1991). Lipoxin formation in fish leucocytes. Biochim. Biophys. Acta, 1084, 303306.
  • SAWAOKA, H., TSUJI, S., TSUJII, M., GUNAWAN, E.S., NAKAMA, A., TAKEI, Y., NAGANO, K., MATSUI, H., KAWANO, S. & HORI, M. (1997). Expression of the cyclooxygenase-2 gene in gastric epithelium. J. Clin. Gastroenterol., 25 (Suppl 1), S105S110.
  • SCHMASSMANN, A., PESKAR, B.M., STETTLER, C., NETZER, P., STROFF, T., FLOGERZI, B. & HALTER, F. (1998). Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br. J. Pharmacol., 123, 795804.
  • SERHAN, C.N. (1994). Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim. Biophys. Acta, 1212, 125.
  • SOUZA, M.H., DE LIMA, O.M., ZAMUNER, S.R., FIORUCCI, S. & WALLACE, J.L. (2003). Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. Am J Physiol, 285, G54G61.
  • TAKAHASHI, S., FUJITA, T. & YAMAMOTO, A. (2000). Role of cyclooxygenase-2 in Helicobacter pylori-induced gastritis in Mongolian gerbils. Am. J. Physiol., 279, G791G798.
  • TANAKA, A., HASE, S., MIYAZAWA, T. & TAKEUCHI, K. (2002). Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J. Pharm. Exp. Ther., 300, 754761.
  • TATSUGUCHI, A., SAKAMOTO, C., WADA, K., AKAMATSU, T., TSUKUI, T., MIYAKE, K., FUTAGAMI, S., KISHIDA, T., FUKUDA, Y., YAMANAKA, N. & KOBAYASHI, M. (2000). Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans. Gut, 46, 782789.
  • THE PINK SHEET (2001). Merck COX-2 cardiovascular safety studies will enrol 30,000 subjects; data will address ‘lingering concerns’. 63, 51.
  • WALLACE, J.L. (1997). Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology, 112, 10001016.
  • WALLACE, J.L., BAK, A., MCKNIGHT, W., ASFAHA, S., SHARKEY, K.A. & MACNAUGHTON, W.K. (1998). Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology, 115, 101109.
  • WALLACE, J.L. & GRANGER, D.N. (1996). The cellular and molecular basis of gastric mucosal defense. FASEB J., 10, 731740.
  • WALLACE, J.L. & MA, L. (2001). Inflammatory mediators in gastrointestinal defence and injury. Exp. Biol. Med., 226, 10031115.
  • WALLACE, J.L., MCKNIGHT, W., REUTER, B.K. & VERGNOLLE, N. (2000). NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology, 119, 706714.
  • WALLACE, J.L. & MILLER, M.J. (2000). Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology, 119, 512520.
  • WALLACE, J.L., ZAMUNER, S.R., MCKNIGHT, W., DICAY, M., MENCARELLI, A., DEL SOLDATO, P. & FIORUCCI, S. (2004). Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. Am. J. Physiol., 286, G76G81.
  • ZAMUNER, S.R. & WALLACE, J.L. (2004). Post-inflammatory colonic dysfunction: role of COX-2 and H-PGD synthase in pre-disposition to colon cancer. Can. J. Gastroenterol., 18, 755 (abstract).
  • ZAMUNER, S.R., WARRIER, N., BURET, A.G., MACNAUGHTON, W.K. & WALLACE, J.L. (2003). Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction. Gut, 52, 17141720.
  • ZIMMERMAN, K.C., SARBIA, M., SCHROR, K. & WEBER, A.A. (1998). Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol. Pharmacol., 54, 536540.